Complete blood count (leukocyte count, platelet count, hemoglobin, and hematocrit) was performed on a Sysmex XN-9000 analyzer (Sysmex Corporation, Kobe, Hyogo, Japan) using EDTA blood. PT (Dade Innovin; Siemens, Marburg, Germany), aPTT (Dade Actin FSL; Siemens), fibrinogen concentration (Clauss method, Dade Thrombin Reagent; Siemens), D-dimer concentration (Innovance; Siemens), and Anti-Xa activity (Biophen Heparin LRT; Hyphen Biomed, Neuville-Sur-Oise, France) were measured on a Sysmex CS2100i (Sysmex Corporation) in 3.2% citrated blood. For the anti-Xa measurement, COVID-19 patient samples (18 μl) were three times diluted with reference pooled plasma (36 μl). Anti-Xa activity was determined using an LMWH calibration line (aXa-LMWH; Hyphen Biomed). UFH activity was subsequently calculated with a previously determined formula: UFH anti-Xa = 1.55 * LMWH anti-Xa (26 (link)). Bilirubin (Bilirubin Total, third-generation; Roche Diagnostics, Basel, Switzerland) and creatinine (Enzymatic Reagent; Roche Diagnostics) were determined in serum on a COBAS® 8000 (Roche Diagnostics).
Free full text: Click here